2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3030

Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development
Abstract Number: 3031

Rethinking Primary Sjögren’s Syndrome: Stratification By Clinical Phenotypes to Improve Understanding of Disease Pathogenesis, Trial Design, Clinical Management and Prospective Health Gains?
Abstract Number: 3032

Abnormalities in the Biological or Haematological Domain of the Essdai Predict an Increase in Systemic Disease Activity the Year after: 5-Year Data from the Prospective Multicenter Assess Cohort
Abstract Number: 3033

Safety and Efficacy of Single Dose VAY736 (anti-BAFF-R mAb) in Patients with Primary Sjögren’s Syndrome (pSS)
Abstract Number: 3034

A Selective JAK1 Inhibitor, Filgotinib Suppresses Lymphocytic Infiltration in Salivary Gland of Non Obese Diabetic Mice Via Suppression of BAFF and Chemokine Production of Salivary Gland Epithelial Cells
Abstract Number: 3035

Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Abstract Number: 3036

IL-22 Is Dysregulated in Psoriatic Arthritis and Acts to Limit IFN-γ Driven Inflammatory Chemokine Production
Abstract Number: 3037

Calprotectin Is Highly Upregulated in Inflamed Axial Entheses in SKG Mice
Abstract Number: 3038

Enumeration and Preliminary Characterisation of Peri-Entheseal Bone Type 3 Innate Lymphoid Cells
Abstract Number: 3039

Anti-IL-17A, but Not Anti-TNF, Can Halt Pathological New Bone Formation in Experimental Spondyloarthritis
Abstract Number: 3040

Th17 Migration into the Synovial Fluid of Patients with Active Psoriatic Arthritis Is Enhanced By Regulatory T Cells
Abstract Number: 3041

Age-Related Defects in the Immune System of Patients with GCA
Abstract Number: 3042

PD-1–Expressing T Cells in GCA Fail to Promote Immune Tolerance Functions
Abstract Number: 3043

Dense Genotyping of Immune Related Loci in a Multi-Ethnic Behçet’s Disease Cohort Identifies Genetic Associations in a Long Noncoding RNA Near QSOX2, RASIP1/FUT2, and IL12A-AS1
Abstract Number: 3044

Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].